(Q36428500)

14 August 2017

1 reference

title

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials (English)

1 reference

14 August 2017

3

Sverre E Kjeldsen

1 reference

14 August 2017

Nisha B Mistry

1

1 reference

14 August 2017

Arne S Westheim

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

5

1 reference

14 August 2017

page(s)

575-581

1 reference

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Addressing those two that go together: the angiotensin II receptors and their role in blood-flow regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Effect of Valsartan on hospitalization: results from Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Effect of valsartan on quality of life when added to usual therapy for heart failure: results from the Valsartan Heart Failure Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.5.575

21 January 2018

Identifiers

DOI

10.1517/14656566.7.5.575

1 reference

14 August 2017

1 reference